Episode 505 : ASCO 2026 - RAMPART
From The Uromigos · · 29 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.